Zapping Tregs

A team at NIH's National Cancer Institute (NCI) has developed a phototherapy that selectively ablates Tregs in tumors to avoid the autoimmune liabilities of systemic immunotherapies.

Despite their impressive efficacy, checkpoint inhibitors marketed to treat cancer cause a range of autoimmune conditions that require careful management, which has prompted a variety of industry and academic groups to explore methods of restricting the immune activation to the tumor microenvironment...